| Pharmaceutical Information |
| Drug Name |
Natalizumab |
| Drug ID |
BADD_D01537 |
| Description |
Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006. |
| Indications and Usage |
For treatment of multiple sclerosis. |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA23 |
| DrugBank ID |
DB00108
|
| KEGG ID |
D06886
|
| MeSH ID |
D000069442
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
64406-008 |
| UNII |
3JB47N2Q2P
|
| Synonyms |
Natalizumab | Tysabri | Antegren |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
189261-10-7 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
